In Vivo DMPK
In Vivo DMPK Evaluation during Drug Discovery
Pharmacology Discovery Services has the experience and skills needed to bring you early stage pharmacokinetic (PK), oral bioavailability and blood-brain barrier (BBB) data to evaluate your new molecular entity. PK and BBB studies are prerequisite for interpreting preclinical efficacy and toxicology results. Using qualitative measurements of drug exposure, we can provide a solid interpretation of preclinical efficacy. PK data can also help in species selection and design of preclinical toxicology studies.
We will work with you to understand the physicochemical properties of your test material to develop a dosing and sample collection strategy that will provide you with the most meaningful data. We can obtain blood and/or tissue (e.g. brain) samples following dose administration (IV, PO, IP, IM, SC, IN, and ICV, also short- or long-term continuous infusions) and both serial sampling for PK and parallel sampling for PK, BBB or combined PK-BBB are available. PK/PD studies can be combined using our broad portfolio of pharmacodynamics models.
PK/BBB dosing and sampling studies can be paired with standard or custom bioanalytical methods to provide a concentration versus time curves to provide a complete pharmacokinetic profile for your compound.
In Vivo Pharmacokinetic and Blood/Brain Barrier Studies with Pharmacology Discovery Services:
- Extensive experience with multiple routes of administration, including long-term continuous infusion
- Proficient in performing PK and BBB studies
- Combined PK/BBB sampling and bioanalytical studies
- Renal and biliary clearance
- Experience you can trust: 30 years running in vivo preclinical services with a staff averaging 15 years of experience
- Long range of efficacy and toxicity studies can be conducted at the same provider
- Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated Nucleosides. Diafuku R et al., Pharmaceuticals (Basel). 2018 Feb 6;11(1).
- 5-aza-2',2'-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer. Diafuku R et al., Pharmaceuticals (Basel). 2017 Jul 20;10(3).
- BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. Papathanassiu AE et al., Nat Commun. 2017 Jul 12;8:16040.
|In Vivo DMPK Models|
|Model Name||Item Number||Species||Price/Animal ($USD)|
|Pharmacokinetics (PK) Study, BBB, In-life, Mouse||515570||Mouse||110|
|Pharmacokinetics (PK) Study, BBB, In-life and Bioanalysis, Mouse||515580||Mouse||275|
|Pharmacokinetics (PK) Study, BBB, In-life, Rat||515520||Rat||160|
|Pharmacokinetics (PK) Study, BBB, In-life and Bioanalysis, Rat||515530||Rat||330|
|Pharmacokinetics (PK) Study, Plasma, In-life, Mouse||515550||Mouse||70|
|Pharmacokinetics (PK) Study, Plasma, In-life and Bioanalysis, Mouse||515555||Mouse||130|
|Pharmacokinetics (PK) Study, Plasma, In-life, Rat||515500||Rat||505|
|Pharmacokinetics (PK) Study, Plasma, In-life and Bioanalysis, Rat||515510||Rat||1000|